![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CPL409116 (CPL’ 116) is an oral JAK/ROCK dual inhibitor which is being investigated for the treatment of Rheumatoid Arthritis.
Lead Product(s): CPL’ 116
Therapeutic Area: Immunology Product Name: CPL409116
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2024
Details:
CPL’280 was designed to improve on the drawbacks of the first generation GPR40 agonists. The molecule, which is structurally different from the first generation agonists, is free from known risk factors associated with liver injury.
Lead Product(s): CPL’280
Therapeutic Area: Endocrinology Product Name: CPL’280
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
Falkieri (esketamine dry powder inhalation) is the antagonist of N-methyl-D-aspartate (NMDA) receptor. It is being developed for Treatment-Resistant Bipolar Depression.
Lead Product(s): Esketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Falkieri
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020